Ipca Laboratories (IPCALAB) Share Price Falls 2.32% to Rs 1,911

Ipca Laboratories Share Price fell to Rs 1,911 on 03 September 2026 at 11:19:38 AM IST, down 2.32% for the day, taking the company’s market capitalisation to Rs 50,384.39 crore. The stock declined by Rs 45.35 from its previous close of Rs 1,956.35, making it one of the healthcare names drawing attention in today’s market update.

For investors trackingIpca Laboratories Share Pricetoday, the verified data confirms a meaningful single-session decline, but it does not establish a company-specific catalyst behind the move. The stock is trending because the price action was notable within a Large Cap pharmaceutical name, while its valuation and profitability metrics remain important: P/E stands at 37.89, P/B at 5.85, ROE at 15.88 and ROCE at 19.41. Investors may also watch how the stock behaves around its intraday low of Rs 1,907.6, how it compares with sector benchmarks, and whether its premium multiples remain supported by returns on capital. Univest data also shows the stock still trading above its 50-day and 200-day moving averages, which adds useful context even on a down day.

Ipca Laboratories (IPCALAB) Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 1,911
Previous Close	Rs 1,956.35
Today's Move	-Rs 45.35 (-2.32%)
Open	Rs 1,959.4
High	Rs 1,970.2
Low	Rs 1,907.6
Turnover	Rs 6.77 crore
Market Capitalisation	Rs 50,384.39 crore
Market Cap Category	Large Cap

Ipca Laboratories Share Price Todayreflects a clear intraday decline, with the stock moving from an open of Rs 1,959.4 to a low of Rs 1,907.6 before trading at Rs 1,911. The gap between the day’s high of Rs 1,970.2 and low shows a broad trading band, while turnover stood at Rs 6.77 crore.

The stock started slightly above the previous close of Rs 1,956.35, touched Rs 1,970.2 early in trade, and then lost ground to Rs 1,907.6. At Rs 1,911, the decline of Rs 45.35 translates into a 2.32% fall for the session. That sequence suggests that early strength did not hold and that sellers had the upper hand through much of the day. Because this is a Large Cap company in the Pharmaceuticals & Drugs industry, today’s decline matters not only as a price move but also as a signal that investors are reassessing near-term positioning. On Univest, this kind of share price fall becomes more useful when read alongside valuation, sector benchmarks and longer-term trend markers.

Ipca Laboratories (IPCALAB) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 50,384.39 crore
P/E Ratio	37.89x
P/B Ratio	5.85x
ROE	15.88%
ROCE	19.41%
EPS	Rs 51.63
Book Value Per Share	Rs 334.38
Dividend Yield	0.31%

Ipca Laboratories Fundamental Analysisshows a Large Cap healthcare company with a market capitalisation of Rs 50,384.39 crore trading at a P/E ratio of 37.89 and a P/B ratio of 5.85. Those valuation multiples need to be read together with profitability, where ROE stands at 15.88 and ROCE at 19.41.

EPS is Rs 51.63, which indicates the earnings attributable to each share based on the supplied data. Book value per share is Rs 334.38, offering the accounting net worth behind each share, while the dividend yield is 0.31, showing a relatively modest historical payout relative to the current stock price. On a simple valuation-to-profitability reading, the company is not cheap on headline multiples alone, but its return ratios are stronger than many industry benchmark levels. That balance helps explain whyIpca Laboratories Share Priceremains on investor watchlists even during a down session. For readers on Univest, the key question is whether current valuation is being supported by sustained operating quality and relative sector positioning rather than by sentiment alone.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	37.89x
Benchmark Median P/E	31.97x
Benchmark Average P/E	48.6x
Benchmark P/E Range	3.49x to 648.54x
Company P/B Ratio	5.85x
Benchmark Median P/B	2.87x
Benchmark Average P/B	4.35x
Company ROE	15.88%
Benchmark Median ROE	11.79%
Benchmark Average ROE	11.15%
Company ROCE	19.41%
Benchmark Median ROCE	13.63%
Benchmark Average ROCE	13.69%
Company Market Capitalisation	Rs 50,384.39 crore
Benchmark Median Market Cap	Rs 727.27 crore
Benchmark Average Market Cap	Rs 14,141.34 crore

The sector data places Ipca Laboratories in Healthcare, specifically Pharmaceuticals & Drugs, and compares it with companies in the same industry. That benchmark matters because it helps show whether today’s stock move is occurring in a company with average, premium or discount valuation and profitability characteristics.

Within a same-industry benchmark scope of 201 companies, Ipca’s P/E of 37.89 sits above the median P/E of 31.97 but below the average of 48.6. The industry P/E range is wide, from 3.49 to 648.54 across 169 companies with available P/E data. On P/B, the company’s 5.85 is higher than the median of 2.87 and the average of 4.35, against a range of -10.61 to 27.8 across 200 companies. Profitability looks firmer: ROE at 15.88 is above the industry median of 11.79 and average of 11.15, while ROCE at 19.41 is above the median of 13.63 and average of 13.69. Market capitalisation also stands out. At Rs 50,384.39 crore, Ipca is well above the industry median market cap of Rs 727.27 crore and the average of Rs 14,141.34 crore, though still far below the industry maximum of Rs 4,63,179.62 crore. On Univest, that combination points to a sizeable listed pharma company with above-benchmark returns but also above-benchmark valuation.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Sun Pharmaceutical Industries	SUNPHARMA	4,63,179.62	38.34	5.36	14.85	19.11
Divi's Laboratories	DIVISLAB	2,43,301.95	83.79	13.88	16.19	21.51
Torrent Pharmaceuticals	TORNTPHARM	1,88,622.52	87.28	21.21	26.76	19.27
Zydus Lifesciences	ZYDUSLIFE	1,16,114.43	25.44	4.26	19.69	21.39
Cipla	CIPLA	1,14,554.33	33.87	3.25	11.83	16

Peer comparison shows Ipca sitting in the middle of the large listed pharma pack on valuation, while its profitability metrics compare reasonably well with several bigger names. The stock is neither the cheapest nor the most expensive among major peers supplied in the dataset.

Ipca’s market cap of Rs 50,384.39 crore is far smaller than Sun Pharmaceutical Industries at Rs 4,63,179.62 crore and Divi's Laboratories at Rs 2,43,301.95 crore, but it also means the company is being evaluated against much larger benchmarks. Its P/E of 37.89 is close to Sun Pharma’s 38.34, above Cipla’s 33.87 and Zydus Lifesciences’ 25.44, yet well below Divi's 83.79 and Torrent Pharmaceuticals’ 87.28. On P/B, Ipca at 5.85 is above Sun Pharma’s 5.36, Zydus’ 4.26 and Cipla’s 3.25, but below Divi's 13.88 and Torrent’s 21.21. Profitability is respectable rather than category-leading: ROE of 15.88 is above Sun Pharma’s 14.85 and Cipla’s 11.83, but below Divi's 16.19, Zydus’ 19.69 and Torrent’s 26.76. ROCE of 19.41 is slightly above Sun Pharma’s 19.11 and Cipla’s 16, broadly around Torrent’s 19.27, but below Divi's 21.51 and Zydus’ 21.39. That placesIpca Laboratories Share Pricein a zone where investors may still expect strong execution to justify current multiples.

Why Investors Are Watching Ipca Laboratories

• The stock fell 2.32% to Rs 1,911, reversing from an intraday high of Rs 1,970.2 to a low of Rs 1,907.6.
• At Rs 50,384.39 crore market cap, it remains a sizeable Large Cap healthcare stock in the Pharmaceuticals & Drugs space.
• Valuation is above industry medians, with P/E at 37.89 and P/B at 5.85.
• Profitability is stronger than benchmark medians, with ROE at 15.88 and ROCE at 19.41.
• The stock is still above its 50-DMA of Rs 1,839.54 and 200-DMA of Rs 1,620.4, despite today’s decline.

About Ipca Laboratories

Ipca Laboratories operates in the Healthcare sector and is classified under the Pharmaceuticals & Drugs industry. Based on the supplied market data, the company sits among established listed pharma names, with a market capitalisation of Rs 50,384.39 crore. Its peer set includes Sun Pharmaceutical Industries, Divi's Laboratories, Torrent Pharmaceuticals, Zydus Lifesciences and Cipla, which places it in a closely watched segment of the Indian pharmaceutical market. For readers followingIpca Laboratories Share Price, that industry position matters because valuation and profitability are often assessed relative to this high-quality listed peer group.

Track Ipca Laboratories Share Price on Univest

UseIpca Laboratories (IPCALAB) live share-price page,Univest top decliners screener,Univest market blogsto review live stock data, top decliners and related market analysis.

On Univest, investors can trackIpca Laboratories Share Pricewith live market updates, valuation ratios, moving averages, 52-week levels, shareholding pattern when available, and broader sector comparisons. For users following daily stock news, Univest helps place one-day price action beside fundamentals, peer metrics and market-cap context, which is especially useful when a large listed healthcare stock records a visible intraday decline.

Frequently Asked Questions

Why did Ipca Laboratories Share Price fall today?

Ans. Ipca Laboratories Share Price fell 2.32% to Rs 1,911 from the previous close of Rs 1,956.35. The supplied data confirms the price decline, but it does not establish any company-specific catalyst behind today’s move.

What is the current price of Ipca Laboratories shares?

Ans. The current price in the supplied dataset is Rs 1,911 as of 03 September 2026 at 11:19:38 AM IST. That places the stock Rs 45.35 below its previous close and near the day’s low of Rs 1,907.6.

How did Ipca Laboratories trade during the session?

Ans. The stock opened at Rs 1,959.4, rose to an intraday high of Rs 1,970.2, and then slipped to a low of Rs 1,907.6 before trading at Rs 1,911. Turnover for the session stood at Rs 6.77 crore.

What is the market capitalisation of Ipca Laboratories ?

Ans. Ipca Laboratories has a market capitalisation of Rs 50,384.39 crore in the supplied data. It is categorised as a Large Cap stock, which makes today’s 2.32% decline notable within the listed healthcare space.

Is Ipca Laboratories expensive compared with its industry?

Ans. On valuation, the company’s P/E of 37.89 is above the industry median of 31.97 but below the average of 48.6. Its P/B of 5.85 is also above the median of 2.87 and average of 4.35.

How profitable is Ipca Laboratories compared with sector benchmarks?

Ans. Ipca’s ROE is 15.88 and ROCE is 19.41. Both are above the same-industry medians of 11.79 and 13.63, and also above the averages of 11.15 and 13.69 in the supplied benchmark set.

What do EPS, book value and dividend yield show for Ipca Laboratories ?

Ans. The supplied data shows EPS at Rs 51.63, book value per share at Rs 334.38 and dividend yield at 0.31. Together, these figures offer context on earnings, net worth backing and historical payout relative to price.

How does Ipca Laboratories compare with Sun Pharma and Cipla?

Ans. Ipca’s P/E of 37.89 is close to Sun Pharma’s 38.34 and above Cipla’s 33.87. Its ROE of 15.88 is higher than Sun Pharma’s 14.85 and Cipla’s 11.83, while ROCE of 19.41 exceeds both peers.

Where does Ipca Laboratories stand within the pharmaceuticals industry?

Ans. Ipca Laboratories is part of the Healthcare sector and Pharmaceuticals & Drugs industry. Its market cap of Rs 50,384.39 crore is far above the industry median of Rs 727.27 crore and average of Rs 14,141.34 crore.

What should investors monitor after today’s decline?

Ans. Investors may monitor whether the stock holds near Rs 1,907.6, how valuation at 37.89 times earnings compares with peers, and whether profitability metrics such as ROE of 15.88 and ROCE of 19.41 continue to support interest.